



Sean Sherlock, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

6th August 2024

PQ: 31552/24

To ask the Minister for Health the expenditure on new medicines and new uses of existing medicines in 2021, 2022 and 2023, in tabular form; and if he will make a statement on the matter. -Sean Sherlock

Dear Deputy Sherlock,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 31552/24), which you submitted to the Minister for Health for response.

An amount of €50m in 2021, €30m in 2022 and €18m in 2023 was allocated in the annual budget for expenditure on new medicines and new uses (licence extensions) of existing medicines.

A number of medicines were approved each year on a cost-minimisation basis relative to existing therapies, i.e. an uplift in pharmaceutical expenditure will not be incurred for those medicines as they have demonstrated budget neutrality.

Where this is the case these new medicines are not reported against, or funded from, the new drug funding received in the budget allocation.

The related expenditure on 2021 new drugs in 2021 was €34.39m, 2022 new drugs in 2022 was €9.36m & 2023 new drugs in 2023 was €18.13m.

Year	Total No. of drugs approved	No. of drugs funded from New Drugs budget				Total funded from budget	Cost in Year 1 €m
		Oncology	High Tech	Community	Hospital		
2021	52	15	17	3	4	39	34.39
2022	60	11	10	1	2	24	9.36
2023	36	7	10	3	2	22	18.13

Please note, the above expenditure relates to expenditure in PCRS only.

Yours sincerely,

A handwritten signature in black ink that reads "Suzanne Doyle". The signature is written in a cursive style with a horizontal line underneath the name.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service